Research and Markets: Understand How Schering-Plough's Ethical Sales Are Set to Grow at a 2004-2010 CAGR of 7.4%, Driven by Remicade, Zetia/Vytorin and the Intron Franchise.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c32972) has announced the addition of Schering-Plough: PharmaVitae Profile 2005 to their offering.

This analysis examines the current position and future outlook for Schering-Plough in the ethical pharmaceutical sector. The profile encompasses global strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts Sales forecast

A key input to a firm's financial planning process. External sales forecasts are based on historical experience, statistical analysis, and consideration of various macroeconomic factors. for key drugs. An interactive forecasting and analysis tool provides continually con·tin·u·al
adj.
1. Recurring regularly or frequently: the continual need to pay the mortgage.

2. updated quantitative and qualitative information.

Reasons to order your copy:

--Benchmark Schering-Plough's performance against key rivals in the ethical pharmaceutical sector

--Understand how Schering-Plough's ethical sales are set to grow at a 2004-2010 CAGR CAGR

See: Compound Annual Growth Rate of 7.4%, driven by Remicade Remicade® Avakine^™, cA2^™, CenTNF^™, infliximab Immunology An agent used to manage severe or mutilating rheumatoid arthritis, or severe or active–eg, fistulizing–Crohn's disease. See Rheumatoid arthritis. , Zetia/Vytorin and the Intron Intron

In split genes, a portion that is included in ribonucleic acid (RNA) transcripts but is removed from within a transcript during RNA processing and is rapidly degraded. franchise

Topics covered include:

--Strategic outlook

--Strategic recommendations

--Current positioning: competitive outlook 2004

--Schering-Plough's forecast revenue stream, 2005-10

--Key issues facing Schering-Plough: 2005-10

--Global company strategy

--Global portfolio and pipeline analysis

--US strategy, portfolio and pipeline

--US Company Strategy

--Corporate development

For more information visit http://www.researchandmarkets.com/reports/c32972

Source: Datamonitor

COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.

Reader Opinion

Article Details
Printer friendly Cite/link Email Feedback
Comment:	Research and Markets: Understand How Schering-Plough's Ethical Sales Are Set to Grow at a 2004-2010 CAGR of 7.4%, Driven by Remicade, Zetia/Vytorin and the Intron Franchise.
Publication:	Business Wire
Geographic Code:	1USA
Date:	Feb 15, 2006
Words:	167
Previous Article:	Relay Capital Corp. Completes Acquisition of First Cash Card.
Next Article:	Get to Grips with Reorganizations under Chapter 11 of the Bankruptcy Code.
Topics:	Franchises Pharmaceutical industry

Related Articles
Fitch Dwngrs Schering-Plough Corp.'s Sr Unsec Debt Rtg to 'A-'; Rtg Outlk is Neg.
FDA Approves VYTORIN -TM- -ezetimibe/simvastatin-, the First and Only Product to Deliver Powerful LDL Cholesterol Reduction Through Dual Inhibition...
This Release Was Previously Issued: FDA Approves VYTORIN -TM- -ezetimibe/simvastatin-, the First and Only Product to Deliver Powerful LDL Cholesterol...
Norwood Abbey Appoints Three USA Based Non-Executive Directors.
Fitch Affirms Schering-Plough Corp.'s Ratings; Outlook is Negative.
Fitch Revises Schering-Plough Corp.'s Rating Outlook to Stable; Affirms 'A-/F2'.
BRIEFCASE.(Business)
Research and Markets: Benchmark Schering-Ploughs Performance against Key Rivals In The Ethical Pharmaceutical Sector.
Schering-Plough fined for off-label marketing, overcharging, kickbacks.
Merck and Schering-Plough to Develop Another New Cholesterol Lowering Medicine.